Cargando…

Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study

BACKGROUND: Bivalirudin is a common anticoagulant during percutaneous coronary intervention (PCI); however, since its application in China, it still lacks comprehensive evaluation of adverse events (AEs) or adverse drug reactions (ADRs) under the real-clinical setting conditions with a large-sample-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ping, Zhang, Hongyan, Luo, Caidong, Ji, Zheng, Zheng, Zeqi, Li, Zhenyong, Wu, Fan, Li, Jinlong, Hong, Lang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099409/ https://www.ncbi.nlm.nih.gov/pubmed/35573935 http://dx.doi.org/10.3389/fcvm.2021.781632

Ejemplares similares

Bivalirudin Presents a Favorable Safety Profile Regarding Adverse Drug Reactions, Thrombocytopenia, and Bleeding in Chinese Patients With High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study
por: Peng, Xiaoping, et al.
Publicado: (2022)

Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients
por: Chai, Lina, et al.
Publicado: (2023)

Is it time to switch to bivalirudin for ECMO anticoagulation?
por: Navaei, Amir, et al.
Publicado: (2023)

Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)

The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article
por: Andreou, Constantinos, et al.
Publicado: (2017)

Selection of an Aptamer Antidote to the Anticoagulant Drug Bivalirudin
por: Martin, Jennifer A., et al.
Publicado: (2013)

Impact of Diabetes Mellitus on One-Year Clinical Outcomes in Patients Anticoagulated with Bivalirudin Undergoing Elective Percutaneous Coronary Intervention
por: Li, Yulong, et al.
Publicado: (2022)

Comprehensive safety profile evaluation of bivalirudin in Chinese ST-segment elevation myocardial infarction patients receiving percutaneous coronary intervention: a prospective, multicenter, intensive monitoring study
por: Zheng, Haijun, et al.
Publicado: (2022)

Primary bivalirudin anticoagulation for patients with an implantable ventricular assist device
por: Pieri, M, et al.
Publicado: (2014)

Bivalirudin vs. heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A multicenter prospective cohort study
por: Yu, Xiao-Fan, et al.
Publicado: (2022)

Periprocedural anticoagulation in transcatheter aortic valve replacement: Heparin vs bivalirudin
por: Minhas, Abdul Mannan Khan, et al.
Publicado: (2017)

Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation
por: Ranucci, Marco, et al.
Publicado: (2011)

Bivalirudin or heparin: which anticoagulation strategy for critically ill cardiac surgery patients?
por: Pappalardo, F, et al.
Publicado: (2014)

Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19
por: Seelhammer, Troy G., et al.
Publicado: (2021)

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
por: Trigonis, Russell, et al.
Publicado: (2022)

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes
por: Farag, Mohamed, et al.
Publicado: (2015)

Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin
por: Ramana, Ravi K, et al.
Publicado: (2008)

Efficacy and Safety of the Reduced Bivalirudin in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention Stratified by Renal Function (REDUCE BOLUS): A Single-Blind, Stratified Randomized, Non-inferiority Trial
por: Hu, Qiang, et al.
Publicado: (2022)

Effects of Heparin and Bivalirudin on Thrombin-Induced Platelet Activation: Differential Modulation of PAR Signaling Drives Divergent Prothrombotic Responses
por: Lund, Mikael, et al.
Publicado: (2021)

The effect of bivalirudin and closure device on bleeding outcomes after percutaneous coronary interventions
por: Dobies, David R, et al.
Publicado: (2014)

Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction
por: Chen, Hongwu, et al.
Publicado: (2020)

Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study
por: Hu, Yue-cheng, et al.
Publicado: (2021)

Bivalirudin Versus Heparin During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
por: Patel, Hiten, et al.
Publicado: (2019)

Superiority of bivalirudin over heparin anticoagulation therapy for extracorporeal membrane oxygenation? Too early to draw conclusions
por: Gu, Jie, et al.
Publicado: (2023)

Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
por: Valdes, Carlos A., et al.
Publicado: (2023)

Management of Bivalirudin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation in Heparin-Induced Thrombocytopenia: A Case Report and a Systematic Review
por: Zhong, Han, et al.
Publicado: (2020)

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

Quantitation of bivalirudin, a novel anticoagulant peptide, in human plasma by LC–MS/MS: Method development, validation and application to pharmacokinetics
por: Li, Xiao-Jiao, et al.
Publicado: (2013)

Ascending aorta thrombosis in a patient with COVID-19 who was already receiving anticoagulation therapy
por: Bouratzis, Vasileios, et al.
Publicado: (2023)

Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis
por: Li, Jiabei, et al.
Publicado: (2015)

Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials
por: Bhogal, Sukhdeep, et al.
Publicado: (2020)

Case report: Oral anticoagulant combined with percutaneous coronary intervention for peripheral embolization of left ventricular thrombus caused by myocardial infarction in a patient with diabetes mellitus
por: Zhu, Chao, et al.
Publicado: (2022)

Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials
por: Bavry, Anthony A., et al.
Publicado: (2015)

Safety and Effectiveness of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
por: Ahmad Hamdi, Abdul Hafeez, et al.
Publicado: (2017)

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
por: Zawawi, Nur Azyyati, et al.
Publicado: (2021)

Lower Plasma Elabela Levels in Hypertensive Patients With Heart Failure Predict the Occurrence of Major Adverse Cardiac Events: A Preliminary Study
por: Ma, Zheng, et al.
Publicado: (2021)

Meta-Analysis of Oral Anticoagulants and Adverse Outcomes in Atrial Fibrillation Patients After Intracranial Hemorrhage
por: Liu, Xin, et al.
Publicado: (2022)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
por: Lin, Dong, et al.
Publicado: (2021)

The Efficacy and Safety of Bivalirudin Versus Heparin in the Anticoagulation Therapy of Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis
por: Ma, Min, et al.
Publicado: (2022)

Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention
por: Tscharre, Maximilian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j3o09rnjs4qbpu5sgb1ehngt8d